Drug Development Pipeline
VX-121 + tezacaftor + VX-561
Restore CFTR Function
This program is studying a combination therapy combining three CFTR modulators. VX-121 and tezacaftor are CFTR correctors, a type of modulator designed to fix the defective CFTR protein so that it can move to the proper place on the cell surface. VX-561 is an altered form of the potentiator ivacaftor (Kalydeco®). Potentiators are drugs that facilitate the opening of the chloride channel on the cell surface to allow chloride and sodium (salt) to move in and out of the cell. VX-561, or deuterated ivacaftor, may be more stable in the body than regular ivacaftor, which would allow it to be taken once a day.
A phase 2 study to test the safety and effectiveness of VX-121 + tezacaftor + VX-561 in adults with CF was completed. Phase 3 studies to test this triple combination therapy are planned.
This program is sponsored by Vertex Pharmaceuticals. This program is being conducted within the Therapeutics Development Network (TDN).
Recent VX-121 + tezacaftor + VX-561 Studies
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More